Marshall Wace LLP Invests $2.62 Million in LifeStance Health Group, Inc. (NASDAQ:LFST)

Marshall Wace LLP bought a new position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 355,924 shares of the company's stock, valued at approximately $2,623,000. Marshall Wace LLP owned approximately 0.09% of LifeStance Health Group as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of LFST. Blue Trust Inc. raised its stake in LifeStance Health Group by 124.4% in the fourth quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock valued at $27,000 after purchasing an additional 2,122 shares in the last quarter. R Squared Ltd acquired a new position in LifeStance Health Group in the fourth quarter valued at about $80,000. Cibc World Markets Corp acquired a new position in LifeStance Health Group in the fourth quarter valued at about $96,000. Handelsbanken Fonder AB acquired a new position in LifeStance Health Group in the fourth quarter valued at about $128,000. Finally, Versor Investments LP acquired a new position in LifeStance Health Group in the fourth quarter valued at about $131,000. Institutional investors and hedge funds own 85.50% of the company's stock.

Insider Activity

In other news, insider Lisa K. Miller sold 18,845 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.90, for a total transaction of $130,030.50. Following the transaction, the insider now owns 339,810 shares in the company, valued at approximately $2,344,689. This represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Canaccord Genuity Group assumed coverage on LifeStance Health Group in a research note on Thursday, April 3rd. They set a "buy" rating and a $8.00 target price for the company. William Blair reiterated an "outperform" rating on shares of LifeStance Health Group in a report on Friday, February 28th. Finally, KeyCorp began coverage on shares of LifeStance Health Group in a report on Tuesday, April 8th. They set an "overweight" rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, LifeStance Health Group has an average rating of "Moderate Buy" and an average price target of $8.30.

LifeStance Health Group Trading Up 0.5 %

LifeStance Health Group stock traded up $0.03 during trading hours on Tuesday, reaching $6.56. 856,600 shares of the company's stock were exchanged, compared to its average volume of 1,617,942. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The firm's 50 day simple moving average is $6.94 and its 200 day simple moving average is $7.30. LifeStance Health Group, Inc. has a twelve month low of $4.64 and a twelve month high of $8.61. The firm has a market capitalization of $2.52 billion, a PE ratio of -25.23 and a beta of 1.30.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.